Friedrich Graf Finckenstein M.D.
Company: Iovance Biotherapeutics
Job title: Chief Medical Officer
The Evolution of Clinical Development for TIL Cell Therapy in Solid Tumors 9:30 am
Delivering broader access to TIL through multi-center studies and scalable manufacturing Clinical Data for TIL in metastatic melanoma, metastatic non-small cell lung and advanced cervical cancers Clinical data for TIL in combination with other therapies in earlier cancer treatment settings Research on genetically-modified TIL as a next-generation approachRead more
day: Day One